If infected, try this to prevent Long COVID
Study: Metformin Associated With 41% Decrease In Long Covid, Here Are The Caveats
https://www.forbes.com/sites/brucelee/2023/06/11/study-metformin-associated-with-41-decrease-in-long-covid-here-are-the-caveats/
Don’t go “metformin” any premature conclusions about the results of this study just yet. But a clinical trial described in a June 8 publication in The Lancet Infectious Diseases found that those taking metformin when sick with Covid-19 were 41% less likely to have eventually developed long Covid than those taking only a placebo. In the trial, 6·3% of those who had received metformin ended up getting diagnosed with long Covid compared to 10.4% of those who had received placebo only. That’s encouraging news because the long and short of it is that doctors currently don’t have any proven treatments for long Covid at their disposal. However, there are a lot of buts, one cannot lie, about the findings from this clinical trial.
Can This Common Medication Help Reduce The Risk Of Long COVID?
https://www.huffpost.com/entry/metformin-long-covid_l_64edff32e4b0fcbba8997137
While this study with metformin has shown good results for some individuals, other methods ― like using paxlovid after an infection ― are also currently being studied as long COVID prevention, too. Because the condition is so new, scientists still need to do lots of research in order to definitively determine the best courses of treatment. However, experts agree these results could be a game changer in the future after more studies are done.
The best way to prevent long COVID now is to do all you can to not get a COVID infection in the first place. Experts still stress the same precautions we’ve known for years are still applicable now
Common diabetes drug shown to prevent long COVID
https://www.cidrap.umn.edu/covid-19/common-diabetes-drug-shown-prevent-long-covid
The reduction in risk may warrant clinicians using the drug in patients sooner rather than later.
Without an alternative treatment of SARS-CoV-2 infection to prevent subsequent long COVID, some providers may choose to prescribe metformin.
Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00299-2/fulltext
In conclusion, early outpatient COVID-19 treatment with metformin decreased the subsequent risk of long COVID by 41·3% during 10-month follow-up. This finding is consistent with the 42·3% reduction in health-care utilisation for severe COVID-19 with metformin in the first 14 days of the trial.